FTC & PBMs: So What?
The FTC's August announcement of its settlement agreement with Merck/Medco Managed care outlined rules governing the PBM's relationaship with Merck & Co. Inc. The FTC's aggressive tone--which suggested that Medco acknowledged that past actions in promoting Merck drugs restricted competition and resulted in higher prices for some drugs--made the agreement seem like a victory for the FTC and upset Medco officials who concede no such things.
You may also be interested in...
Pink Sheet reporters and editors dig into the emerging coronavirus vaccine regulatory schedule, look at vaccine purchasing trends, and consider the curious case of a federal government billboard encouraging convalescent plasma donations.
Siemens Healthineers' acquisition of radiation oncology company Varian Medical Systems creates an oncology giant. Analysts disagree on whether its the right move for the companies.
Pfizer is up against AstraZeneca and Sanofi in developing competing approaches to tackling the unmet need in respiratory syncytial virus (RSV). But earlier failures mean all players will need much more data to sway regulators.